However, the only clinically- validated treatment for stroke now available is acute thrombolysis tissue-type plasminogen activator (tPA), and the utilization of this approach is constrained by the need to initiate treatment rapidly after the stroke onset and the risk of causing cerebral hemorrhage [1]. This evidence concerns the gene PLAT and stroke disorder.